Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
Our data highlight the potential utility of ctDNA in optimising patient selection, improving therapeutic monitoring, and dissecting genomic mechanisms of resistance to [<sup>177</sup>Lu]Lu-PSMA-617, and further prospective validation is warranted.
Authors
- Nicole Ng (ORCID: https://orcid.org/0000-0001-6614-4427)
- Tú Nguyen‐Dumont (ORCID: https://orcid.org/0000-0002-6217-0182)
- Jason A. Steen (ORCID: https://orcid.org/0000-0003-1351-5815)
- Sebastián Casanueva Eliceiry
- Sathya Manoharan (ORCID: https://orcid.org/0000-0001-9676-0458)
- Patricia Bukczynska (ORCID: https://orcid.org/0000-0001-8021-1657)
- Siavash Foroughi (ORCID: https://orcid.org/0000-0001-6916-8424)
- Elizabeth Medhurst
- M. Awad
- Louise Kostos (ORCID: https://orcid.org/0000-0001-6072-5175)
- James P Buteau (ORCID: https://orcid.org/0000-0001-5693-2913)
- Michael S. Hofman (ORCID: https://orcid.org/0000-0001-8622-159X)
- Maria Docanto
- Heidi Fettke (ORCID: https://orcid.org/0000-0002-5784-3338)
- Arun Azad (ORCID: https://orcid.org/0000-0001-7350-5622)
Institutions
- Walter and Eliza Hall Institute of Medical Research (AU)
- Peter MacCallum Cancer Centre (AU)
- Monash University (AU)
Publication Details
- Journal
- European Urology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.eururo.2025.08.015
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04